skip to content National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Skip to subnavigation.
Programs & Resources
skip sub-navigation, go to content.

Rapid Access to Preventive Intervention Development (RAPID) Program

Projects and Investigators

FY 2000 Projects

Fels Institute for Cancer Research and Molecular Biology

Objective

Development of DHEA-analog, Fluasterone, for efficacy trials in cancer prevention.

Program Description

Investigators will conduct preclinical development of DHEA-analog, Fluasterone, for efficacy trials in cancer prevention. The already developed synthetic steroid, fluasterone (16a-fluoro-5-androsten-17-one), which like its naturally occurring counterpart, adrenocortical steroid DHEA (dehydroepiandrosterone) exhibits chemopreventive activity in laboratory rodent models. However, fluasterone unlike DHEA lacks sex hormonal and liver perixosome proliferating effects. RAPID support will include studies:

  • Chronic preclinical toxicology studies in dog and rat,
  • Synthesis of C-14 fluasterone,
  • Preclinical absorption, distribution, metabolism, elimination and pharmacokinetic.

Contact Information

Arthur G. Schwartz
Temple University School of Medicine,
Fels Institute for Cancer Research and Molecular Biology
Pennsylvania
Tel: 215-707-4349
Fax: 215-707-7473
E-mail: ags@temple.edu